Publication date: Jun 24, 2025
High-extraction protease inhibitors (e. g., for HIV and COVID-19) typically require ritonavir to enhance bioavailability by overcoming first-pass metabolism. However, in the long-acting subcutaneous injectable dosage form TLC-ART 101, lopinavir persisted in plasma for 57 days, while ritonavir was detectable for only 3-7 days. The remarkable duration of lopinavir suggests that ritonavir may be unnecessary in long-acting injectable products, potentially reducing side effects and drug-drug interactions.
| Concepts | Keywords |
|---|---|
| Dosage | boosting |
| Eliminates | clinical pharmacology |
| Hiv | HIV |
| Pharmacokinetic | injectables |
| Tlc | long acting |
| lopinavir | |
| pandemics | |
| protease inhibitors | |
| ritonavir |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Lopinavir |
| drug | DRUGBANK | Ritonavir |
| disease | MESH | COVID-19 |
| pathway | REACTOME | Metabolism |
| disease | MESH | drug interactions |
Original Article
(Visited 1 times, 1 visits today)